COMMUNIQUÉS West-GlobeNewswire
-
NARMAFOTINIB Large-Scale Manufactre Complete
22/01/2026 -
Privia Health to Report Fourth Quarter 2025 Results on Thursday, February 26
22/01/2026 -
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
22/01/2026 -
What Are the Top Customer Experience Trends for 2026? New Transcom Report Identifies Five Paradoxes CX Leaders Must Address
22/01/2026 -
SPR Announces Eight Featured Posters and Presentations at NANS 2026
22/01/2026 -
Cannabix Marijuana Breath Test Featured on the Cover of AlcoPro’s 2026 Product Catalog
22/01/2026 -
Human Continuum Appoints Dr. Omar Khalid Sial, Ph.D., as its Chief Scientific Officer to Spearhead the Development of Innovative Extracellular Vesicle Topical Formulations and Advanced Biologic Therapies
22/01/2026 -
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
22/01/2026 -
ProPhase Labs Uplists from Pink Sheets to OTC Market
22/01/2026 -
Tilray Medical Strengthens Italian Market Presence with the Launch of Tilray Medical Italia and Expanded Medical Cannabis Portfolio
22/01/2026 -
Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development U.S.
22/01/2026 -
Catheter Precision Receives First Purchase Order for LockeT in Germany
22/01/2026 -
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
22/01/2026 -
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
22/01/2026 -
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
22/01/2026 -
Vivani Subsidiary Cortigent to Present Orion System’s Advanced Brain Implant Technology in Poster Session at NANS 2026
22/01/2026 -
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board
22/01/2026 -
SweetWater Introduces Big Trip Double IPA: A Bold New Craft Beer
22/01/2026 -
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
22/01/2026
Pages